Aliri Bioanalysis vs Certara

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/aliribio/certara

Category	Aliri Bioanalysis	Certara
Listed site	cro	cro
Summary	Bioanalytical CRO specializing in PK/PD, biomarker, and spatial imaging services across discovery through Phase 3 clinical trials, with 20+ years of regulatory expertise.	Certara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.
Services	LC-MS Bioanalysis (Small Molecule) Bioanalysis Biomarker Assays Pathology & Histology Services In Vivo PK / PD Studies GLP Toxicology Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Discovery Research Translational Research Regulatory Affairs In Vivo Efficacy Models Preclinical In Vivo Studies Target Identification & Validation Clinical Imaging Core Lab Ligand-Binding Bioanalysis (Large Molecule)	Biostatistics & Statistical Programming Data Management & eClinical Regulatory Affairs Medical Writing Computational & In-Silico Drug Discovery Translational Research Target Identification & Validation High-Throughput Screening Medicinal Chemistry In Vitro Pharmacology In Vitro ADME / DMPK Safety Pharmacology Genetic Toxicology Discovery Research In Vivo Efficacy Models In Vivo PK / PD Studies GLP Toxicology Preclinical In Vitro Studies Preclinical In Vivo Studies Bioanalysis LC-MS Bioanalysis (Small Molecule) Ligand-Binding Bioanalysis (Large Molecule) Phase I Clinical Trials Biomarker Assays Phase II Clinical Trials Phase III Clinical Trials Clinical Operations Phase IV / Post-Marketing US FDA Regulatory Strategy US FDA Regulatory Strategy EU EMA Regulatory Strategy EU EMA Regulatory Strategy Japan PMDA Regulatory Strategy Japan PMDA Regulatory Strategy China NMPA Regulatory Strategy China NMPA Regulatory Strategy Clinical Trial Services
Modalities	Small Molecule Biologics (Monoclonal Antibodies) Antibody-Drug Conjugate (ADC) Oligonucleotide Peptide	Small Molecule Small Molecule Biologics (Monoclonal Antibodies) Biologics (Monoclonal Antibodies) Biologics (Other) Biologics (Other) Peptide Peptide Oligonucleotide Oligonucleotide mRNA mRNA Antibody-Drug Conjugate (ADC) Antibody-Drug Conjugate (ADC) Gene Therapy Gene Therapy Cell Therapy Cell Therapy Vaccine Vaccine
Indications	Data not yet provided.	Oncology Rare Disease Immunology Immunology Neurology Neurology Psychiatry Metabolic Metabolic Cardiovascular Cardiovascular Infectious Disease Infectious Disease Respiratory Respiratory Dermatology Dermatology Ophthalmology Ophthalmology Gastroenterology Gastroenterology Nephrology Nephrology Women's Health Women's Health
Locations	Headquarters, Colorado Springs, Colorado, United States Utah, Salt Lake City, Utah, United States France, Loos, Hauts-de-France, France Office, Salt Lake City, Utah, United States Office, Loos, Nord, France Salt Lake City, Salt Lake City, Utah, United States Loos, Loos, Hauts-de-France, France	Global network Global presence, 30 countries Global presence, Multiple, 30 countries, Global Global presence, Multiple, 30+ countries Global presence, Multiple, 30 countries, International Headquarters, Radnor, Pennsylvania, United States Global presence, 30 countries Global presence, 30+ countries
Certifications	Data not yet provided.	Data not yet provided.
Reviews	Review summary appears after site-level review signal gate opens.	Review summary appears after site-level review signal gate opens.